Applications of micromachined devices to malaria and cancer detection by Hardin, James O. (James Otey)
Applications of Micromachined Devices to Malaria and Cancer
Detection
by
James O. Hardin IV
B.S. Polymer and Fiber Engineering
Georgia Institute of Technology, 2005
B.S. Physics
Georgia Institute of Technology, 2005
SUBMITTED TO THE DEPARTMENT OF MATERIAL SCIENCE AND
ENGINEERING IN PARTIAL FULFULLMENT OF THE REQUIREMENTS FOR
THE DEGREE OF
MASTER OF ENGINEERING IN MATERIAL SCIENCE AND ENGINEERING
AT THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
SEPTEMBER 2006
© Massachusetts Institute of Technology. All rights reserved.
Signature of Author:
yI
James O. Hardin IV
Department of Material Science and Engineering
August 4, 2006
Certified by:
Accepted by:
Subra Suresh
Ford Professor of Engineering
/? Thesis Supervisor
Samuel M. Allen
POSCO Professor of Physical Metallurgy
Chair, Departmental Committee on Graduate Students
MASSACHUSETTS INST'rIT E,
OF TECHNOLOGY
NOV 0 2 2006
LIBRARIES
ARCHNES
__ __

Applications of Micromachined Devices to Malaria and Cancer
Detection
by
James O. Hardin IV
Submitted to the Department of Material Science and Engineering on July , 2006 in
Partial Fulfillment of the Requirements for the Degree of Master of Engineering in
Material Science and Engineering
ABSTRACT
Of the many micromachined diagnostic devices currently being developed, suspended
microchannel resonator technology seems unique in that is not a scaling down of an
existing technique and does not require labeling of the target cell. This technology has the
potential to become an important diagnostic tool of diseases that cause a change in the
mechanical properties of cells in blood. Malaria and cancer are good examples of this
type of disease and both could benefit from more effective testing methods. For this to
be accomplished, complementary technologies like filtration and microfluidic
interconnects will also have to be developed. However, substantial funding will be
required for this development. The cancer market appears to be the most favorable by an
order of magnitude in terms of funding. There are many business strategies to take
advantage of this technology. Each has its own set of risks and possible gains.
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Chapter 1: Introduction and Overview
Malaria and cancer are major threats in two very different worlds. Malaria primarily
affects the poor in countries that have not managed to control the disease. Cancer is
generally a disease affecting older people and only diagnosed as something other than
"getting old" in countries with developed medical services. Although the worlds that
malaria and cancer scourge are very different, there is a real potential that micromachined
diagnostic devices might be effective at identifying both conditions. However,
successfully identifying a condition is just the beginning. Ideally, a detection device will
effectively (with high sensitivity and selectivity) and quantitatively detect the condition
in time for effective treatment, and at a price that is not only affordable to those who need
it but also profitable to the manufacturers.
There are currently many kinds of micromachined diagnostic device being developed.
Most are based on current diagnostic and detection methods like PCR and flow
cytometry. Basically, they are labs on chips. Although these devices can have lower test
times and higher precession, they operate with fairly low volumes. Doing an analysis
with small volumes means less material consumption but also less chance of detecting
rare cells. Suspended microchannel resonator (SMR) technology seems unique in that it
is not a scaling down of an existing technique. Furthermore, it does not require complex
chemistry or labeling, and it is capable of giving quantitative information about a sample.
For these reasons, it is the focus of this paper.
The effectiveness of the device depends on its ability to detect the disease. By trapping
cells of interest in the resonator, their mass can be identified and a diagnosis made.
Small changes in the mass of the resonator yield changes in the resonant frequency of the
suspended channel which can be measured. There are two main methods for trapping a
cell, chemically binding the cell to the wall of the resonator, and restricting the
microchannel in the resonator so that the cell cannot pass through it.
The exact effectiveness of SMR based detection devices is far from actually being
tested, but a general idea of that effectiveness can be estimated. Depending on the
prevalence of a particular cell in the blood, the time required for an effective test can vary
from minutes to years and take from milliliters to 10 liters. Both of these factors are also
limited by the time scale of the disease progression and the total blood in a person's
system. There may be further multipliers to the test length when the natural variation in
cell size and properties is taken into effect. There is also a chance that the filtration
system that prepares the whole blood for the SMR may remove some of the cells that the
device is seeking.
Technical issues aside, there must be a market to support the development and
manufacture of this device. Malaria research totals approximately 300 million US dollars
per year worldwide.' Most of this money is focused on new drug development and
education in endemic areas. 1 Cancer research is 5 billion US dollars just in the US for the
National Cancer Institute in 2006. 2 Many of the cancers of inner organs like the pancreas
currently have no effective and noninvasive test. Malaria treatment markets are probably
in the high hundred million to low billion dollars per year world wide. Cancer treatment
markets are on the order of hundreds of billions of dollars worldwide per year, $72.1
billion just in the US in 2004. 3 SMR devices, being a technology that still requires a large
amount of development, currently need the funding that only cancer research offers at
this time. Although a functional device may be made using malaria research funding, it
will still need a great deal of development to adapt it to the harsh field conditions of the
current malaria market. Rapid dipstick tests went into this field without proper
preparation and failed to live up to expectations. In the process, they lowered the trust of
the people in need of testing and therefore made the market that much harder to access.
There are many business models that can be used to commercialize this technology.
Depending on the amount of investment available before commercialization, different
models are possible to try. When taking into consideration the current state of
technology in the field of rare cell detection, it would probably be wisest to outsource
manufacturing and focus on development to get a functional commercialized device more
rapidly.
Chapter 2: Technology
Suspended microchannel resonators were developed by Professor Scott Manalis's
group at MIT. The SMR has already proven its capacity to detect small masses of
proteins.4 Research by Professor Subra Suresh's group has quantified the change in
mechanical stiffness of red blood cells (RBC's) upon infection by the malaria parasite, P.
falciparum, using optical tweezing.5 The mechanical and temperature dependent
properties of RBC's infected with the other species of the malaria parasite still need to be
assessed. This group has also investigated the change in cell stiffness of metastatic
pancreatic cells. By restricting the flow in the microchannel of the SMR, it is possible to
screen for a target cell based on its size and stiffness. This method is built around testing
single cells in solution. Bodily fluids, such as blood, are a natural source of cell
containing fluids.
Blood is a complicated material. It contains cells and chemicals with many different
chemical and physical properties. There are two types of cells in the blood. Red blood
cells are the cells responsible for the movement of oxygen and carbon dioxide in the
body. These cells are some of the smallest and lack nuclei. White blood cells vary
greatly in size and structure and are larger than red blood cells. These cells mediate
immune response.
To isolate the cells of interest, the others have to be filtered out. This changes the
chemical surroundings of the cells. Furthermore, flows though typical artificial systems
have very different flow characteristics, flow rate and pressure, than flows though vessels
in the body. Chemical and flow changes can induce changes in cell behavior. However,
such effects can only be investigated and compensated for once prototype systems are
constructed. Capillaries have the peculiar property of having laminar flow even in
relatively complex branches. Fortunately, microfluidic channels have similar properties
and, therefore, make the testing apparatus a better simulation for the natural environment
of blood.
For the purposes of malaria diagnosis, the 8 pm diameter red blood cells (RBC's) are
the cells being tested. There are about four to six million of these cells per ptL of blood.
For cancer diagnosis, it is the nucleated cells larger than 10 pLm that are being tested.
There are about five to ten thousand of these cells per gpL of blood. This means that a test
to identify cancer will probably require a large opening in the restrictive channel in order
to be effective. In other words, SMR based devices made for malaria detection may not
work for cancer detection.
2.1 Filter
(a) (b)
Figure 2.1. Example of the Microfluidic Filtration Techniques. Bent microchannels (a)6
act as a centrifuge on a chip. Plasma skimming (b)7 is a more complicated effect.
Traditional filters either function as a sieve or a sand box. The sieve restricts the size
of particles that can pass. The sand box slows particles based on their size and can
effectively act as a sieve but has less certainty. Microfluidic devices have opened up the
field of filtration. Now there are two microfluidic methods of filtration. Bent
microchannels, Figure 2.1 (a), can simulate the effect of a centrifuge and segregate
particulate matter in the fluid based on mass. Plasma skimming, Figure 2.1 (b), allows
for the removal of the blood plasma and lymphocytes from whole blood. The actual
mechanism of plasma skimming is a complex interaction between the cells, fluid, and
capillary walls but has been empirically found to follow equations 2.1 to 2.3.
F* = aQ* + (1-a)/2 (2.1)
a = (1.4 - x1/2)-1 (2.2)
X= d/d (2.3)
F* is the fractional of RBC flow entering a daughter branch, marked with "*" in Figure
2.1 (b), a is the plasma skimming parameter, Q* is the fractional volumetric flow entering
the daughter branch, X is a dimensionless length, dc is the diameter of the RBC's, and d is
the diameter of the parent vessel.8
When using a filter with SMR technology, there is a chance that the already small
number of infected cells may be reduced even further. In a properly designed system, it
seems unlikely that this reduction could be more than an order of magnitude. The current
plan is to use a proprietary filter technology from Innovative Microtechnologies (IMT).
2.2 SMR
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Figure 2.2.9 Diagram of an SMR with One Channel. The effect of proteins attaching to
the walls of the suspended microchannel can be seen in b-d.
The suspended microchannel resonator is fabricated using micromachining,
photolithography, CMP, and reactive ion etching. The whole process takes on the order
of a day to complete.4 A single resonator may have one or multiple channels through
which a fluid may flow. The interior of each channel can be coated with a material that
chemically traps the target or the channel can be restricted to mechanically interrogate
what is passing through. Currently, the resonance is determined via electrostatic
actuation and laser lever measurement. However, the next generation of test chip will be
using piezoelectric sensors to measure the frequency.
Before being tested the fluid of interest must be prepared. Ideally, the fluid is diluted
so that simultaneous capture does not distort the mass measurement. Care must be taken
to ensure that the sample fluid does not contain particles that could become permanently
lodged in a channel thus rendering it useless. Phosphate buffered saline (PBS) is often
used to dilute a blood sample to an acceptable level. Heparin is also added to prevent
clotting.
Mechanical interrogation of cells is the primary method of differentiating the target
cells from other cells for this embodiment of SMR technology. In order for a cell to be
captured by the restricted microchannel, it must be larger than the channel and stiff
enough to be stopped for a long enough period to be detected. The majority of the cells
in the blood are red blood cells. These cells are around 8 gpm in diameter but extremely
flexible. The other cells that are typically in the blood are white blood cells. These cells
are orders of magnitude less common and vary in size from 10 to 30 gpm. Other cells in
the body are in the same size range as the white blood cells but not as flexible.
2.3 Interconnects
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Figure 2.3.10 Nonreversible Microfluidic Interconnect. The air vent help prevent bubbles
in the plastic outer sheathe that seals the connection. Note that there is no dead space in
the final connection (b).
A great deal of development has taken place in designing microfluidic devices.
However, relatively little time has been spent on how to connect these devices to the
outside world and to each other. For the sake of assembly and repair, these interconnects
need to be functional, fast, easy, and reversible. Functionality means that the seal has to
be able to withstand the chemicals, temperatures, and pressures of the system. A good
connection also needs to avoid dead volume. Dead volume refers to places in the fluid
channels that are not in the flow of the liquid. Cells and chemicals can get stuck in these
dead volumes and come out in another sample, thus causing contamination. Fast, easy,
and reversible basically refers to the "plugging" and "unplugging" the components.
Making the connection to the microfluidic device reversible is not advisable because of
the length scales involved. Many microfluidic devices can be easily damaged by the
forces exerted on them from direct interconnects." It is generally better to package the
chip in such a way that its connections to the system are larger, mesoscopic, and easier to
manipulate.
One method of packaging the SMR has already been developed and tested. 12 It
basically consists of a PDMS gasket that fits over the resonator and separates the section
of the chip where the fluid resides from the evacuated section that contains the resonator.
The gasket is made using soft lithography and also contains the electrode for electrostatic
stimulation of the resonator. A diagram of this process can be seen in Appendix II.
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2.4 Noise
Any events that occur with a frequency below the noise threshold of a diagnostic
device are not meaningful. The sources of noise are far too numerous to list but there are
a couple worth mentioning. There is a noise level in the blood itself. This noise stems
from variations in blood either from cell damage or from mutations. Mutations occur in
about one in 106 to 109 cells. Since the SMR effectively tests two aspects of the cell, size
and stiffness, then two mutations might be necessary to produce a false positive. This
makes the noise from mutation range from 1/1012 to 1/1018. In other words, the noise
becomes negligible. Other chemicals put into the system also have a noise associated
with them but they are similarly negligible. There is also a noise inherent in the system.
However, this noise can only be investigated once prototypes are built.
Cells that are not native to the blood but not indicators of the particular ailment of
interest can also cause noise. These cells are typically larger and therefore require large
breaches in the wall of the vessel to enter the blood stream and larger vessels to move in.
This means that the concentration of these cells should vary depending on how the blood
sample is taken. There are many sources of these cells, from major bruises to damaged
internal organs. Therefore, the concentration of these cells that managed to get into the
blood stream may vary greatly, depending upon the patient. This source of biological
noise will have to be further investigated.
2.5 Testing Method Terminology
When discussing testing methods, frequently used terms should be defined. The terms
used in this paper are sensitivity, selectivity, chance of false positive, and chance of false
negative. Sensitivity (Sn) is the chance that a test is positive given that the patient is
positive. Selectivity (S1) is the chance that a test is negative given that the patient is
negative. The chance of false positive (fP) and false negative (fN) is the chance that the
test result is not accurate. Sensitivity and selectivity are connected to the chance of false
positive or false negative by the equations below:
___ I __ 1___11·__ls___··_··_
SI= 1- fP
Sn= 1- fN
Repeatability and reproducibility are also important terms for testing methods.
Repeatability is the ability to repeat a test at the home facility and get the same results.
Reproducibility is the ability of a test to be reproduced at another facility. Repeatability
and reproducibility tests (R&R) are usually performed as part of developing a testing
method.
2.6 Limitations
Even without a working prototype of the final SMR technology to be used, it is
possible to make some estimates on the limitations of a technology that takes a blood
sample and analyzes it for abnormal cells. Primarily, if you know how rare a cell is, you
can estimate how many tests are necessary to decrease the chance of false negative to an
acceptable level, less than 10%. Furthermore, an adult body contains only around 5L of
blood. A test that would deplete a person to a dangerous level would not be useful.
Finally, if a test takes too long per sample, it is hard to perform economically. All of
these considerations are displayed in Table 2.1.
0
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Table 2.1. Summary of Limitations. Yellow indicates regions that are acceptable for
cancer testing, blue for malaria, and green for both. The chance of false negative, (a),
should be less than 0.10. The time to complete test, (b) based on test rates from 300 to
300,000 cells per second, and the blood volume, (c), needed to provide that
corresponding number or white or red blood cells is also displayed.
m
There are ways that these limitations can be overcome. For example, an implanted
version of the SMR could continuously test the blood stream of the patient thus relaxing
the test time and blood volume restrictions. The economical aspect of the test time
restriction could also be relaxed by massive parallel testing. However, these solutions
come with their own sets of problems. For example, any implanted device will have to
overcome the harsh internal environment of the human body and also go through the
arduous path of FDA approval.
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Chapter 3: Malaria
Malaria is a disease that has devastated man throughout history. Almost every attempt
to take and hold Rome was foiled by malaria. The Goths, Attila, and several others took
the city but had to quickly abandon it when malaria appeared. It is believed that even
Alexander the Great was killed by this disease. Throughout most of recorded history,
malaria has been associated with water. Water is the source of mosquitoes, the vector for
the parasite that causes malaria.
The malaria parasite varies greatly from species to species but only four infect
humans, P. vivax, P. malariae, P. ovale, and P. falciparum. The malaria parasite infects
liver cells, then red blood cells (RBC's). It is characterized by flu symptoms with a
periodic fever. The lack of selectivity of the clinical symptoms of malaria makes it hard
to differentiate from other infections and therefore hard to effectively treat.1 3 Of the four
species, only P. falciparum is particularly dangerous to healthy adult humans. The
danger of P. falciparum is its tendency to sequester itself in organs. The sequestered
RBC's can cause blockages in blood vessels which lead to a broad range of
complications.
Since malaria typically appears in poorer, less developed countries, the data about the
disease is not reliable. 14' 15 Figure 3.1 gives a general idea for the areas most effected by
malaria. Many of those who are diagnosed with malaria are not properly tested. Many
do not consider testing to be worthwhile because the test often costs more than the
treatment. However, the proliferation of cheap anti-malarial drugs has led to certain
strains developing resistance. P. falciparum is the predominant drug-resistant species but
some strands of P. vivax are also becoming drug resistant. As the cheap treatment
options become less effective, testing will likely become more important.
Figure 3.1.16Areas Affected by Malaria. This map shows locations where malaria is
common as well as area where drug resistant malaria is present
However, resistance in the malaria parasite is not the only problem. Resistance in the
anopheles mosquito, the primary vector for the disease, is also becoming a problem.
More and more mosquitoes are becoming resistant to DDT and other pesticides. As both
the vector and the parasite become resistant to our means of controlling them, malaria
may begin to threaten developed nations once again. India has recently seen a comeback
of malaria and some cases are even occurring in the US. In 10 years, what has been a
disease of the poor for most of living memory, may return to strike at kings and
conquerors once again.
Most of the areas that have managed to eradicate malaria have only eradicated the
parasite and not the vector. All that is necessary for malaria to gain a foothold in these
areas is a significant collection of people infected with a resistant strain of malaria
moving into the area. Migrant workers from endemic countries would not only have the
numbers to infect an appreciable number of mosquitoes, but they also tend to reside in the
poorer areas where the residential structures are not as resistant to infiltration by
mosquitoes. However, the relatively high building standards of most of the US make
this country fairly resistant to major outbreaks because anopheles mosquitoes generally
only feed from dusk to dawn.
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Figure 3.2.ass7 Range of the Anopheles Mosquito. The anopheles mosquito is the primary
vector for malaria.
The rate that resistance is seen in the malaria parasite varies greatly. Some treatments
even start showing signs of being resistant the first year they are being used; while others
can go for a decade without showing signs of resistance.1 8 Resistance is expected to occur
because of the natural diversity in most species. However, there are many strategies that
can slow the time it takes for resistance to form. The most common is basically a
massive assault. If none of the species survive an assault, then there will be no second
generation with higher resistance. A bit more elegant solution is to use combination
therapies that attack two critical mechanisms of the parasite. This makes adapting to
either component harder because the parasite must survive both. Both of these methods
increase the cost of treatment.
One should not be under the impression that even the perfect testing device would be a
silver bullet for dealing with malaria. Malaria is as much a social, economic, and
political problem as it is a medical one. Transportation, water treatment, and education
are required for coping with the disease and impeded by the disease. For example, an
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infected sanitation officer cannot treat the local water to kill the mosquito larva. Because
of this, more malaria carrying mosquitoes are born and infect more sanitation officers.
Diseases that affect as many people as malaria does tend to follow vicious cycles such as
the one illustrated in Figure 3.3.
Slowed economic
development
Civil Unrest
Figure 3.3. Example of the cycles impeding the annihilation of malaria in many endemic
areas.
3.1 Existing Technology
Several test methods have been developed over the years with varying degrees of
success. The "gold standard" is optical microscopy of blood samples. These blood
samples are often stained and observed under a particular light to check for visible
indicators of infection. This method is cheap and can be performed with just a
microscope. However, the effectiveness of this method relies on the skill and diligence
of the technician. In the areas where testing is most needed, highly skilled and diligent
technicians are very rare.19
In hopes of reducing the effect of human error on the results, several other test
methods have been developed. The Buffy spin coat test takes advantage of infected
RBC's being heavier than healthy ones. Polymerase chain reaction (PCR) searches for a
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specific DNA sequence that is associated with the particular strain of the malaria parasite.
Rapid dipstick tests (RDT's) and ELISA tests look for a particular protein characteristic
of malaria. Each of these testing methods has certain strengths and weaknesses but none
of them has really filled the need. Table 3.1 gives a basic idea of how these tests
compare. RDT's came closest to filling the need but failed because of inconsistent
manufacturing and poor effectiveness in the field. 20, 21 Nonetheless, these tests make a
good reference point for what is needed. Their failure is a good lesson in what can go
wrong.
Cost/test Advantage Disadvantage
Microscopy $0.30 Gold Standard Very operator
dependent
RDT $1.00 Fast and effective in Neither under field
controlled setting condition
ELISA $10.00 Slow and requires a Effective
lab
PCR $15.00 Slow and requires a Effective
lab
Table 3.1. Overview of malaria diagnostic methods. 22
23
'
24
3.1.1 Rapid Dipstick test
Rapid dipstick tests (RDT's) came onto the market in the 1990's and were quickly
accepted because of their speed, price, and effectiveness. RDT's could test for each
strain of malaria as well as malaria in general. The more a test could differentiate, the
more expensive the test was. The test for P. falciparum generally screened for LRP-2.
LRP-2 stays in the blood for up to 28 day after an infection.25 This means that the P.
falciparum RDT had a fairly large blind spot. For a month after an infection, the test
would be unable to determine whether another infection had occurred. However, it
became apparent that their effectiveness was not what was advertised. This led to many
attempts to improve effectiveness by controlling transportation and storage of the tests.
This sensitivity of the test to environmental conditions led to an increase in indirect
costs. However, the effectiveness of the tests did not improve enough to remain an
acceptable diagnostic method. RDT's are still on the market under names such as
PARAsight and NOW malaria test. However, faulty testing does not just deprive people
of proper treatment; it also shakes their faith in the system. Despite the low cost, speed,
and possible sensitivity of RDT's, there does not appear to be much academic research on
this type of test, but there may still be research in industry.
Figure 3.4.25 Picture of OptiMal test and results
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3.1.2 ELISA
Enzyme-linked immunosorbent assay (ELISA) is one of the procedures currently in
use to diagnose HIV. It detects either the antigen or the antibody specific to the infection
in question by binding it to a surface and then binding an enzyme to the antigen or
antibody. Another material is added after all of the unbound material is washed off, that
is broken down by the enzyme and produces a measurable change, usually color. This
method effectively magnifies the concentration of the target antigen or antibody because
the enzyme reacts with several color-changing molecules for every antibody or antigen
caught. The basic method is outlined in Figure 3.5.
The current method involves several hours of work and quite a bit of wet chemistry.
Both of these aspects disqualify it from being used for malaria detection. However, there
are some lab-on-a-chip devices being built that may reduce the time and complexity of
this detection method.24
3.1.3 PCR
Polymerase chain reaction (PCR) is a method used to look for a particular chain of
DNA. The process starts with the isolation of DNA from the sample. The sample can be
almost any cell containing material from blood to feces. The concentration of a particular
DNA strand is amplified via means chemically similar to those used in living cells. This
amplification is then run through electrophoresis to make the results visible. However,
there are only one or two copies of a gene per cell. In other words, normal PCR does not
help overcome a low concentration of cells. On the other hand, if the gene is actively
being expressed, there may be several mRNA strands that were transcribed from the
DNA. These mRNA stands can be converted to DNA by use of reverse transcriptase, and
the standard PCR process can take it the rest of the way. In order to speed up the process
and eliminate the need for electrophoresis following the PCR, fluorescent dyes can be
incorporated into the process to mark positive matches as they happen. This method is
called real time PCR. However, the equipment required to run this type of PCR can be
prohibitively expensive.
There has been recent work on moving PCR to a lab-on-a-chip implementation. The
components necessary to accomplish this are out there but the small volumes processed
by the system also mean small sample volumes and therefore adversely affect the
sensitivity of the test. The economics and effectiveness of lab-on-a-chip PCR remains to
be seen.
3.2 Markets
In order to estimate the potential market for malaria treatment the WHO mortality
statistics were used as a starting place for calculating the number tests required.28
Assuming the 0.5% of the cases of malaria were fatal, an estimate of the total number of
cases can be drawn out. Approximately 30% of those with a clinical diagnosis of malaria
actually have the disease but all of these need to be tested.20 So, a final figure for the
number of tests was determined and broken down by country. Countries with very little
malaria were then removed from the list. But not every country can afford testing. To
__ __·_ __. IIC_··_
estimate the amount a country could afford to spend on malaria detection, 4% of a
endemic country's GDP29 was assumed to go to healthcare and 40% of that went to
malaria." Currently, diagnostic equipment is a negligible part of the budget for many
malaria treatment programs, but 1% was assumed due to the good chance of diagnostics
becoming more important as drugs become more expensive. The general trend between
what a country can afford to spend per test and what it needs is displayed in Figure3.6.
The actual numbers and the associated countries can be found in Appendix I.
No current effective
testing technology
90% of tests needed
Testing technology
availible
10% of tests needed
$0.00 $0.20 $0.40 $0.60 $0.80 $1.00 $1.20 $1.40 $ 60 S1.80 S2.00
Price Payable
Figure 3.6. Tests Need Versus What Monetary Resources are Available Per Test. The
vast majority of those who need testing are not able to pay.
Although SMR is not likely to be immediately available to those who need it, there
may still be markets in the military and foreign aid organizations. These organizations
have the money not only for the proper treatment of the malaria but also a culture that
would accept a test that curtailed unnecessary drug usage. Countries like India,
Indonesia, and China also have enough a need for testing and a capacity to afford it.
They might provide early markets as well as long as a significant portion of those
affected are in the socioeconomic classes with the money. Even if the larger markets are
the ultimate goal, these smaller markets can be used as sources of valuable experience
and development.
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3.3 Competition
Competition in the malaria market comes in many forms. There are the existing
technologies and their derivatives, but there are also vaccines, pesticides, and education
that can cut into the market by reducing the total need. The current state of technology
has been discussed above and future extensions of technology are hard to anticipate.
Many of the above methods have been moving to lab-on-a-chip implementations that are
rather similar to SMR in appearance. However, even should these products become
commercially available; they will probably still remain too expensive for the malaria
market. The SMR chip is relatively simple compared to the PCR or ELISA chips and
seems easier to make cheaply. Advancements in methods of treating malaria seem
unlikely to eradicate the disease on their own and are typically more expensive than their
predecessors. The necessity and expense of these new treatments make effective
diagnostics more important.
Vaccines, on the other hand, are an aspect of competition that could easily wipe out
the market. Because of the complex life cycle and adaptability of the parasite, effective
vaccines have thus far eluded medical science. The parasite has a plethora of different
antigens it can present without mutating. 30 Unlike the common vaccines, a malaria
vaccine would have to target multiple antigens. Research of vaccines is still underway
and making progress. Exactly when a vaccine will appear is hard to say but it would not
be surprising for one to appear in the next 20 years. Such an appearance would spell an
ending to funding on many aspects of malaria research because all of those with the
money would no longer have anything to fear from the disease. Once the vaccine reaches
an appropriately low price, the countries currently suffering from the ravages of malaria
may even benefit, but that is far in the future.
Chapter 4: Cancer Detection
When a tumor metastasizes its cells become more mobile and spread to other parts of
the body. They can move through tissue, lymph, or blood. Of these, blood is the easiest
to extract without doing harm. However, the size of tumors varies greatly and so does the
number of metastatic cells released into the blood stream. Cancers of tissue that are
heavily vascularized normally, such as the lung, tend to release more cells into the blood
stream. In some of these cases the concentration of metastatic cells in the blood can be
1/106 nucleated blood cells. 31 Some studies have shown detection of metastatic cells from
pancreatic and gastric cancers in the blood at 1/10 7 cells but not reliable detection. 32'
33
High concentrations of metastatic cells in fluid generally indicate advanced, incurable
cancer. The key to detecting cancer before the disease has progressed too far may be
detecting 1/108 nucleated blood cells.
Detection of rare cells by testing a blood sample not only requires complicated test
methods and a careful test control but also is limited by the patient's well being. There
are about 4,500 to 10,000 nucleated cells per gtL of blood. In order to reduce the chance
of a false negative of a rare cell test, approximately 1 billion cells must be tested. This
converts into 100mL of blood. Should the metastatic cancer cells be on the order of
1/10 9, then the test would require about a liter of blood, according to Table 2.1. For
many patients, a liter of blood is acute blood loss. This basically means that 1/108 is the
limit of the blood sample tests that most patients are familiar with.
4.1 Market
The primary drivers in the cancer diagnostic market are effectiveness and price.
However, the restriction on price is nowhere near as strict as that for malaria detection.
Cancer is primarily a disease of affluent people. 34 The cancer market is also segmented
into section for each type of cancer. The amount of money available in each cancer
market varies depending on the incidence of that cancer and the current capacity of
technology to identify it at a stage that can be treated. These markets generally vary from
hundred of millions to billions of US dollars. Because early diagnosis is critical for
effective treatment, placing this technology as a screening technology, used at regular
checkups, is key to its success.
SMR evaluation of the blood can only tell someone that they have a metastasized
tumor, not that they are about to form one. This information is only useful in the very
early stages of metastasis or after treatment to confirm continued remission. Since there
are more people than people who have cancer, the market for diagnosis of the early stages
is much larger than the latter market. In many cases, even regular screening with SMR
may not be effective.
4.2 Existing technology
PCR and flow cytometry are the main two techniques used for rare cell detection.
Both of these use a cell type specific molecule to detect metastatic cells. Both of these
techniques have also been around for a while and are still developing. The current limit
for both of these techniques appear to be 1/10 7 nucleated blood cell detection.35
Flow cytometry uses dyes. The key dye is the one that marks the target cell. Other
dyes are used as reference points to take out sources of error such as dead cells. The
process starts with dyeing the cells and then flowing them single-file through a tube. The
presence or absence of a dye is detected with an optical system. If the target cell dye was
charged, then the target cells can be separated out at the conclusion of the test and
subjected to further testing, if necessary. This process can be seen in Figure 4.1.
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Many cancers also secrete chemicals into the blood stream that can be detected.
However, there are often many conditions that can lead to an increase in the amount of a
particular secretion. Cancers of the B cells are an interesting case where the secretions
can be characterized in a very selective manner. Typically cancers come from a single
cell. B cells produce either K or X light chains. The light chains are used to construct the
Y shaped antibodies. In a normal person there is a fairly consistent ratio between K and
X, but in patients with cancers of the B cells, a much different ratio is seen because this
cancer only produces K or k, not both. Free light chain (FLC) analysis can be used to
detect this ratio.37
4.3 Competition
Competition for the cancer market is of a more classic type than the malaria market.
There are companies that have either commercialized or are developing devices that can
serve the same need as SMR. There are other companies that hold patents to important
parts of a microfluidic device. The most interesting of the competitive companies are
Agilent and bioMerieux. Of course, these are not the only players. There are many
other companies working on technologies that might, or already do, extend into the
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Figure 4.1. 36 Diagram of Flow Cytometry.
cancer diagnostics market such as Affymatrix, Caliper Life Science, and Gamera
Bioscience.
Agilent has recently released a lab-on-a-chip technology, Bioanalyzer, for PCR and
flow cytometry. 38 For PCR, this technology has sped up the process of electrophoresis
but has not taken out the chemistry involved in purifying and amplifying the DNA
strands. Although Bioanalyzer is not a direct threat in the rare cell detection market, its
existence does imply a functional interconnect system for a single chip and possibly for
an array of chips. In other words, Agilent could represent a potential threat if it were to
develop a lab-on-a-chip device that could test whole blood with minimal modifications or
a potential partner if it took interest in SMR technology.
An alternative to PCR, called nucleic acid sequence base amplification (NASBA), is
being used in some devices by bioMerieux. Where PCR primarily focuses on DNA,
NASBA focuses on RNA. Otherwise, the processes seem, at least superficially, similar.39
Supposedly, it is a more effective test and does not require thermal cycling.40 NASBA
tests take from about 90 minutes to run.41
Since there does not appear to be a technology like SMR around at the moment, the
supporting technologies are the main source of intellectual property competition.
Specifically, the interconnect and packaging intellectual property space is already being
populated. Sandia Corporation, Kionix Inc., and Cepheid are just three examples of
companies occupying this space.
Although some early lab-on-a-chips devices are available now, complete complicated
tests on one chip appear to be a few years off. Even once they are available, it will
probably take a few years to deal with unanticipated issues. So it seems safe to say that
lab-on-a-chip devices for common testing methods like PCR and ELISA could be
available within 5 years. The force they will ultimately exert in the market place will
depend on their effectiveness, ease of use, cost, and reliability.
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Chapter 5: Business Model
The various options for commercializing this technology will be presented in the order
of increasing infrastructure to implement. To some degree it represents a natural
progression of a business based on a technology where choices at each stage affect the
viability of later stages. These business models are based on a SMR technology that has
developed to the point that a prototype detection device has been made or will be made
very soon. Currently, the SMR chip is still being tweaked. Before choosing a model it
would be worthwhile to purchase a professional analysis of the cancer diagnostics and
medical device market. This should amount to around $3,000.42
5.1 Licensing
In this model, licensing of technology and engineering support are the main sources of
revenue. Continuous development is also necessary in order to keep the critical and
valuable IP and one of the main expenses. The fees that are part of patent filing and
maintenance are the other major expenses. Licenses must be carefully considered and
limited. A license that is too broad can block licenses into other markets at a later time
that may be more lucrative. It is also best to try to license the technology to a
manufacturer that performs a high value step so that the royalties are then larger. For
example, it would be better to license the SMR technology to a company making the
entire diagnostic device than just the chip because 1% of $500, the price of the number of
chips in the device, is much smaller than 1% of $30,000, the price of the device.
Special care has to be taken when developing technologies that will be primarily
marketed to the governments, especially if the development was funded in part by a
government because they are then licensed to use the IP. For example, if the US
government funded the development of a SMR based testing device and decided that they
only needed 10 to serve their needs, they could just have them made at government
facilities and totally cut the firm who actually developed the technology out of the loop.
To estimate the cost of such a business one can assume a small team of five engineers
at $100,000 per year for salaries and benefits. There will also be support personnel. One
can assume a research facility will need three at $50,000 for each. These support
personnel could be technicians, machinists, administrative assistants, or represent fees for
contracting a patent lawyer or specialist scientist. That brings personnel costs to
$650,000. The materials and facilities will be dominated by the cost of prototypes
because they represent a small scale run at a MEMS fab and are therefore very expensive.
For the purposes of this paper, it will be assumed that prototypes will run about $500,000
a year. This brings the total to $1,150,000 a year to operate a small development crew.
It is quite possible for this type to operate for years without actually licensing
anything. It also quite possible for the costs to increase by multiples if the core five
engineers do not have a particular area of specialty and the prototypes end up requiring a
particularly rare and hard-to-perform technique to manufacture. The markets associated
with cancer detection devices is hundreds of millions of US dollars per cancer type per
year. The markets that may exist for the detection of malaria may be comparable to that
of only one type of cancer and are harder to access. A business using this model will
probably struggle to make money.
5.2 Diagnostic Equipment Development
In this model diagnostic equipment is sold to labs that are probably already aware of
the technology's existence. The actual manufacturing of the device will be outsourced,
but development and quality control will still be in-house. Quality control is one of the
keys for developing a brand association with quality. Although this does not have as
great an effect in very small or new markets, success will breed competition and branding
can effectively extend the protection offered by patents. The cost of these devices is
estimated in Table 5.1. In the diagnostic market, these devices should go for $30,000 to
$50,000 based on a RT-PCR machine.43
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Chips X 500 $2,500
Board and interconnects X 10 $2,500
UI X 1 $3,000
Assembly, QC, and Misc. X 1 $2,000
Total $10,000
Table 5.1. Estimate for Cost of Cancer Diagnostic Device.
Malaria diagnostic devices would cost less because they require fewer chips but also
need to be more robust. Ideally, the device will be sold for a price that is in the low
hundreds of dollars, but this does not leave much room for expensive components.
Assuming the development costs from above and keeping with minimalist estimations,
this model will require an additional two people at $80,000 each and $2,000 a year in
testing equipment and supplies. That brings the total to $1,332,000 a year. In a worst
case scenario, this means that 67 machines must be made and sold each year to break
even. Whether the market will actually support this remains to be seen, and depends
strongly on how effective the device is.
5.3 Screening Equipment Development
In this model, screening equipment is sold to labs, hospitals, and doctors' offices.
Typically, it is only used for slower-developing diseases like cancer and arterial sclerosis.
Unlike the diagnostic equipment market, those who are purchasing this equipment may
not be aware of its existence and are unlikely to fully understand the principles by which
it operates. This makes communication with existing and potential customers important
enough to invest in marketing. Since the world of medical marketing is a very hands-on
one, it would probably be beneficial to hire a fulltime marketing team. The user interface
of the device would also have to be simplified. This will likely include additional
programming, redundancies, and other modifications to make the device user friendly.
All of this extra work should result in a larger market and a device that sells for hundreds
of thousands of dollars, which is in the same price range as a mammogram machine.
Extending from the previous estimates, this model should require the addition of 4
marketing personnel for domestic sales. Assuming $120,000 salary for each and an
expense budget of $200,000 to pay for travel, brochures, conferences, and other
miscellaneous costs; an effective marketing program brings the total to around
$1,892,000. However, this is probably the point where a leadership position that
coordinates and focuses all departments is necessary. Assume this position costs another
$200,000 and the total becomes $2,092,000 per year. Furthermore, the cost of
manufacturing devices for this market could easily double because of higher required
levels of robustness (idiot-proofing) and user friendly interfaces. Fortunately, these
devices can be sold for an order of magnitude more than their diagnostic predecessors.44
5.4 Device manufacturer
In this model a plant is built and staffed to make the device and sell it. This process is
time consuming but eliminates the markups from the various levels of assembly.
However, many of these steps, such as wafer making and processing, are commoditized.
It is quite reasonable to assume that it would take 5 years to build the plant and train the
facility to produce the device at the price that existing manufacturers charge for the work.
Assuming that development of a SMR device that can be commercialized will take 5
more years, then there will only be another 10 years left on the life of the patent. Of
course, this also assumes that the commercialized embodiment does not include new IP
that resets the IP protection timer. It also assumes that no competition appears and takes
control of the market in the next decade. Both of these assumptions are not reasonable.
At this point in the development of the technology, an estimate of the cost associated with
a manufacturing facility would not be meaningful.
5.5 Testing Agency
The most involved strategy is to develop, build, and use the testing equipment for
cancer diagnosis. Revenue would come from those paying for the tests. The primary
expenses would be the equipment, development, marketing, testing facilities, and staff. It
would also be beneficial to have a strong presence in committees determining the testing
policy. The choice to pursue this option has to be made fairly early in the development
process. Should important IP be licensed out or too much functional equipment be sold
to fund development, the technology will have expanded too far to be easily recaptured
into one company. This timescale depends heavily on the lifetime of early stages of the
commercialized device. If these devices can function for decades without support from
the manufacturer, then it would be fairly easy for machines sold for early capital to create
competition for the testing agency later. To get around this, these early machines could
be leased instead of sold. This means that the existing machines, outside for the testing
agency, can be recalled when it is time to actually open the doors to customers. Any
competitive technology that arose could erode the customer base drastically or destroy a
business based on this model.
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Chapter 6: IP Strategy
Intellectual property (IP) of medical devices has to be carefully managed because of
the long time frame development issues. Furthermore, it is unlikely that the malaria
market will get to a position in the immediate future to support research and development
of the malaria diagnosis application. That being said, should resistant strains of malaria
continue their rise, the malaria market could open up a great deal. Should this occur after
the expiration of the SMR patent, that is not of particular concern because the packaging
(user interface, filters, casing, etc) is probably the key intellectual property. With good
planning and good luck it should be possible to hold key IP for SMR technology for
decades.
Initially, the SMR patent should protect the technology from being copied. However,
SMR is not the only mass spectrometry technology capable of measuring the small
masses quickly. Any mass spectrometry technology that can be modified for fast analysis
can eventually threaten the preeminence of SMR for diagnostic applications. In order to
avoid this, the patents on the final devices need to refer to the SMR by its function first
including specificity later, if necessary. Although this will not allow expansion into the
other mass spectrometry technologies, it will facilitate the blocking of those technologies
from entering this application. This being an initial patent, it may not last for the entire
functional lifetime of the technology but, hopefully, it will last for most of the needed
time for the cancer diagnosis application.
Before extending into the malaria diagnostic market, several factors must be
considered. These factors are the prevalence of disease, the state of drug treatment, the
state of vaccination development, and the spread of disease to developed nations. If the
disease appears to have stabilized in third world nations and is almost nonexistent in
developed nations, then a diagnostic device is not needed and pursuing the IP associated
with it would not be worthwhile. If new drug treatments for malaria are still the lion
share of malaria research and there is still an improper use of existing drugs, then the
costs of treating malaria are likely to increase and make accurate diagnosis more
important. One of the real killers of malaria diagnostic devices would be an effective
vaccination. Although it is unlikely that many of the areas currently affected by malaria
would be immediately affected by a vaccine, it would hold the attention of the developed
nations and, therefore, most of the money. All judgments on these factors need to
emphasize a long term view. Trust in a diagnostic method is often conferred upon the
first method to effectively perform the task. If this device is only unveiled when it is
common knowledge that such a device is needed, it will have many competitors. If the
device is unveiled too soon, the IP covering it expires before it can be fully utilized.
Assuming that conditions are favorable for a new malaria detection device, then it is
unlikely that all of the knowledge of packaging will be immediately available.
Partnerships with companies like Fluke may be useful because of their experience in
developing rugged packaging for sensitive equipment. Although military manufacturers
might seem like the most reasonable place to start for rugged device manufacture, they
are motivated by factors other than those that will necessarily produce an effective
medical diagnostic device. The most powerful IP here will be the packaging and
arrangements for sharing this IP via partnerships. Should important discoveries occur
during the cancer development phase that would also be critical to the malaria diagnosis,
then one should ensure that these pieces of IP are properly managed because they
represent leverage against partners in the negotiation of right to the IP that is ultimately
commercialized.
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Chapter 7: Conclusions
Achieving the 1/108 level of rare cell detection before other technologies, may open up
a huge market in cancer diagnostic screening for SMR based devices. However, there are
still many technical issues to be overcome. The use of the piezoelectric sensor to
measure the resonance is needed to make running of many chips in parallel feasible.
Development of a good interconnect system is necessary for easy assembly and part
replacement. This should enable the economical use of the large arrays of chips that are
necessary for cancer screening.
The timeframe is hard to estimate because the first prototype device has not been built
yet. It is also hard to tell how soon the competitive technologies will extend beyond the
1/10 7 level of detection. However, it seems unlikely that SMR will be the sole occupant
of that space. The size of the cancer screening market is very seductive but the efficacy
of the device has to be proven. The level at which SMR can detect metastasis may be too
late for effective treatment. However, the test may still prove useful as a tool to
understand how metastatic cells move through the circulatory system.
The existing markets for malaria detection are very small and therefore not very
forgiving. The most reasonable course of action seems to be low cost development, such
as in a university, until such time as the market opens up more or it becomes apparent
that this market will never open up. How to make the device robust in field conditions is
a major issue for this application and may require industrial partnerships with those who
have experience in packaging sensitive equipment.
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Appendix I
US Name # of Tests required US$ to malaria detection Price per test
Malawi 11,856,581 1,220,640 0.10
Liberia 3,939,677 414,880 0.11
Niger 13,959,793 1,632,000 0.12
Guinea-Bissau 1,492,123 176,160 0.12
Tanzania 33,616,557 4,259,200 0.13
Congo, Democratic Republic of the 57,907,354 7,403,200 0.13
Congo, Republic of the 2,972,328 403,200 0.14
Mali 13,459,176 1,892,800 0.14
Sierra Leone 5,610,778 801,920 0.14
Zambia 11,436,373 1,644,800 0.14
Nigeria 129,660,919 21,136,000 0.16
Burkina Faso 15,235,437 2,710,400 0.18
Benin 7,399,739 1,388,160 0.19
Madagascar 13,228,830 2,531,200 0.19
Central African Republic 3,560,137 715,200 0.20
Mozambique 20,187,633 4,094,400 0.20
Comoros 287,638 70,560 0.25
Burundi 2,764,837 709,120 0.26
Cote d'lvoire 14,851,947 3,969,600 0.27
Somalia 2,800,478 772,000 0.28
Uganda 24,447,935 7,355,200 0.30
Chad 9,716,036 2,928,000 0.30
Guinea 9,970,412 3,318,400 0.33
Togo 3,866,336 1,442,880 0.37
Angola 10,633,387 4,425,600 0.42
Senegal 7,823,135 3,289,600 0.42
Cameroon 11,692,041 5,176,000 0.44
Eritrea 1,453,212 715,360 0.49
Ethiopia 18,907,419 9,588,800 0.51
Kenya 10,706,121 6,312,000 0.59
Ghana 13,849,404 8,288,000 0.60
Mauritania 1,554,273 989,600 0.64
Gambia, The 768,952 495,040 0.64
Rwanda 1,755,157 1,798,400 1.02
Sudan 13,125,280 13,673,600 1.04
Gabon 712,755 1,284,960 1.80
Cambodia 2,019,973 4,593,600 2.27
Laos 726,596 1,907,200 2.62
Burma 4,215,704 12,192,000 2.89
Yemen 819,511 2,752,000 3.36
Papua New Guinea 520,889 2,131,200 4.09
Namibia 450,963 2,524,800 5.60
Afghanistan 558,489 3,440,000 6.16
Equatorial Guinea 508,682 4,110,400 8.08
Vietnam 2,563,429 40,288,000 15.72
Vietnam 2,563,429 40,288,000 15.72
Zimbabwe 224,963 3,836,800 17.06
Egypt 2,906,549 54,064,000 18.60
Haiti 110,259 2,070,400 18.78
Sri Lanka 616,889 13,875,200 22.49
Botswana 95,164 2,662,400 27.98
Indonesia 4,082,665 143,840,000 35.23
Thailand 2,354,964 87,328,000 37.08
Bangladesh 989,101 47,984,000 48.51
Pakistan 949,352 61,632,000 64.92
Nepal 66,397 6,747,200 101.62
India 5,542,189 588,480,000 106.18
Iran 466,552 88,256,000 189.17
Iraq 73,038 15,056,000 206.14
Philippines 275,556 72,208,000 262.05
Colombia 134,519 48,496,000 360.52
Brazil 370,370 252,800,000 682.56
China 221,138 1,305,280,000 5902.56
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